BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s stock price rose 3.9% during trading on Wednesday . The stock traded as high as C$14.50 and last traded at C$14.50. Approximately 3,717 shares changed hands during trading, an increase of 35% from the average daily volume of 2,750 shares. The stock had previously closed at C$13.95.
BriaCell Therapeutics Stock Performance
The stock’s fifty day simple moving average is C$15.29 and its two-hundred day simple moving average is C$22.38. The stock has a market capitalization of C$27.32 million, a P/E ratio of -0.23 and a beta of 3.21.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC).
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Gold Loves Trump as Much as Trump Loves Gold
- Why Invest in High-Yield Dividend Stocks?
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
